Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1105 participants.
Also called NCT02930018
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,105 participants
- Sponsor
- Registry
-
NCT02930018
-
- Other papers using this trial's data
- Association of baseline infarct size, reperfusion grade and intracranial hemorrhage in patients undergoing thrombectomy
- Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
- Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial
- Infarct Evolution on MR-DWI After Thrombectomy in Acute Stroke Patients Randomized to Nerinetide or Placebo: The REPERFUSE-NA1 Study
- Infarcts in a New Territory: Insights From the ESCAPE-NA1 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Germany, Ireland, South Korea, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02930018. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-01 (actual); primary completion 2019-11-20 (actual). Results posted on 2020-12-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
- Acronym
- ESCAPE-NA1
- Condition
- Stroke, Acute
- Intervention (Drug)
- Nerinetide (NA-1), 2.6 mg/kg
- Intervention (Drug)
- Placebo
- Lead sponsor
- NoNO Inc.
- Collaborator
- University of Calgary
Record details
- Record id
cardio:ct-nct02930018- Content hash
056dabf66f5ebfb4b261cc2c86e2df1fa717cca0a159d8907167d6ca0c39c161